Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Health Economic and Policy Issues Regarding Cancer
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Health Economic and Policy Issues Regarding Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 16 March 2026 | Viewed by 1001

Special Issue Editor

Prof. Dr. Aviad Tur-Sinai

E-Mail Website
Guest Editor
School of Public Health, University of Haifa, Haifa, Israel
Interests: cancer economics

Special Issue Information

Dear Colleagues,

We are pleased to announce a call for papers for a Special Issue in Cancers, titled "Health Economic and Policy Issues Regarding Cancer".

This Special Issue explores the complex intersection of economics, policy, and cancer care. We invite original research, systematic reviews, and perspective pieces examining both supply-side concerns (drug and medical supply costs, healthcare infrastructure) and demand-side factors (out-of-pocket expenses, insurance coverage, healthcare utilization). We welcome studies addressing economic challenges across the lifespan—from pediatric cancer care to middle-aged populations and elderly patients with unique needs. Topics may include cost-effectiveness analyses of novel therapies, financial toxicity's impact on patients, equitable resource allocation strategies, and innovative policy approaches to sustainably financing cancer care. We particularly welcome manuscripts addressing global disparities, value-based care implementation, and policy interventions balancing innovation with affordability. This Special Issue aims to provide evidence-based insights for clinicians, policymakers, payers, and healthcare administrators working to optimize the value of cancer care while ensuring system sustainability.

We invite authors from diverse disciplines, including health economics, health management, public health, sustainability science, and related fields, to contribute to this Special Issue. Both conceptual and empirical papers using qualitative, quantitative, or mixed-methods approaches are welcome.

Prof. Dr. Aviad Tur-Sinai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer economics
  • health policy
  • cost-effectiveness
  • financial toxicity
  • healthcare disparities
  • value-based oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 1139 KB  
Article
Cost-Effectiveness of Sacituzumab Govitecan Versus Chemotherapy in Metastatic Triple—Negative Breast Cancer in Taiwan
by Shyh-Yau Wang, Yun-Sheng Tai, Henry W. C. Leung, Shin Hang Leung and Agnes L. F. Chan
Cancers 2025, 17(20), 3305; https://doi.org/10.3390/cancers17203305 - 13 Oct 2025
Viewed by 710
Abstract
Objective: This study evaluated the cost-effectiveness of sacituzumab govitecan (SG) compared with single-agent chemotherapy of the physician’s choice (TPC) from the perspective of Taiwan’s National Health Insurance. Methods: A partitioned survival model was developed to assess outcomes in patients with metastatic triple-negative breast [...] Read more.
Objective: This study evaluated the cost-effectiveness of sacituzumab govitecan (SG) compared with single-agent chemotherapy of the physician’s choice (TPC) from the perspective of Taiwan’s National Health Insurance. Methods: A partitioned survival model was developed to assess outcomes in patients with metastatic triple-negative breast cancer (mTNBC). Clinical data were derived from the ASCENT trial, while direct medical costs were obtained from Taiwan’s National Health Insurance Administration (NHIA). Utility values were taken from published literature. The primary outcome was the incremental cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life year (QALY) gained. One-way and probabilistic sensitivity analyses were performed to examine parameter uncertainty and test the robustness of the results. Results: In the base-case analysis, SG was associated with an incremental cost of USD 121,836 per QALY gained—exceeding Taiwan’s willingness-to-pay (WTP) threshold of USD 102,120. One-way sensitivity analyses indicated that SG drug cost was the primary driver of ICER variability. Probabilistic sensitivity analysis showed that reducing the price of SG by 50% increased the likelihood of cost-effectiveness. Conclusions: From the NHIA perspective, SG is not cost-effective for patients with advanced or metastatic TNBC at its current price. Substantial price reductions would be required for SG to become cost-effective under the WTP threshold of USD 102,120 per QALY. Full article
(This article belongs to the Special Issue Health Economic and Policy Issues Regarding Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

21 pages, 1066 KB  
Systematic Review
A Systematic Review of the Cost-Effectiveness of Screening Modalities for Breast Cancer in European Countries
by Zacharoula Sidiropoulou and Vasco Fonseca
Cancers 2025, 17(21), 3585; https://doi.org/10.3390/cancers17213585 - 6 Nov 2025
Viewed by 143
Abstract
Background: Breast cancer remains the most diagnosed cancer in European countries, with diverse screening modalities requiring economic evaluation for optimal resource allocation. This systematic review evaluated the cost-effectiveness of breast cancer screening strategies across European healthcare contexts. Methods: We conducted a comprehensive search [...] Read more.
Background: Breast cancer remains the most diagnosed cancer in European countries, with diverse screening modalities requiring economic evaluation for optimal resource allocation. This systematic review evaluated the cost-effectiveness of breast cancer screening strategies across European healthcare contexts. Methods: We conducted a comprehensive search across PubMed, ScienceDirect, Cochrane Library, Scopus, and Google Scholar following PRISMA guidelines (1990–2024). Studies were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Economic standardization employed healthcare-specific inflation indices and purchasing power parity adjustments, with costs converted to 2020 EUR. Results: From 1449 studies, 23 met inclusion criteria, with significant geographic imbalance (74% from North-Western/Central Europe, 4% from South-Eastern Europe). Mammography screening for women aged 50–69 years demonstrated consistent cost-effectiveness (EUR 3000–8000 per quality-adjusted life year (QALY)) with high confidence. For women under 50, screening showed substantially higher costs (EUR 105,000 per year of life saved). Magnetic resonance imaging (MRI) screening showed cost-effectiveness for high-risk populations (EUR 18,201–33,534 per QALY) with moderate confidence. Conclusions: Biennial mammography screening for women aged 50–69 demonstrates consistent cost-effectiveness across European contexts. Findings have highest applicability to North-Western and Central European healthcare systems, with limited generalizability to Southern and Eastern Europe due to evidence gaps. Full article
(This article belongs to the Special Issue Health Economic and Policy Issues Regarding Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop